Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

58.68
-0.0700-0.12%
Volume:1.46M
Turnover:85.63M
Market Cap:33.85B
PE:31.48
High:59.54
Open:58.95
Low:58.35
Close:58.75
52wk High:64.38
52wk Low:34.63
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.36
T/O Rate:0.37%
Dividend:0.91
Dividend Rate:1.55%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:4.95
PE(LYR):32.94

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Royalty Pharma price target raised to $70 from $66 at Citi

TIPRANKS
·
Aug 06

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Reuters
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Royalty Pharma PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Benzinga Earnings
·
Aug 05

Royalty Pharma Q2 Net Income Falls, Revenue Rises

MT Newswires Live
·
Aug 05

Royalty Pharma Q2 GAAP Net Income Attributable to Company Falls 44% to $18 Million; Non-GAAP Adjusted Ebitda Rises 16% to $736 Million

Reuters
·
Aug 05

Royalty Pharma Q2 Adjusted Ebitda Beats Estimates

Reuters
·
Aug 05

Royalty Pharma Reports Second Quarter 2026 Results

THOMSON REUTERS
·
Aug 05

Royalty Pharma: Outlook 2026 Portfolio Receipts $3,400 Mln to $3,500 Mln, Interest Paid $350 Mln to $360 Mln

THOMSON REUTERS
·
Aug 05

Royalty Pharma Names Greg Raskin SVP, Head of Academic Initiatives

Reuters
·
Aug 03

Royalty Pharma Appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

THOMSON REUTERS
·
Aug 03

Earning Preview: Royalty Pharma plc revenue is expected to increase by 1.34%, and institutional views are bullish

Earnings Agent
·
Jul 29

Royalty Pharma Acquires Royalty Interest in AstraZeneca's Cliramitug

MT Newswires Live
·
Jul 22

Royalty Pharma Buys Cliramitug Royalty Stake from Neurimmune for up to $425 Million

Reuters
·
Jul 22

Neurimmune: in Q1 of 2027, Royalty Pharma Will Provide Another $125 Mln in Cash to Co

THOMSON REUTERS
·
Jul 22

Neurimmune Sells a Portion of Its Royalty Interest in Cliramitug to Royalty Pharma

THOMSON REUTERS
·
Jul 22

Neurimmune: Sold Portion of Its Royalty Interest in Cliramitug to Royalty Pharma for up to $425 Mln

THOMSON REUTERS
·
Jul 22